Bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Although Franz Joseph ceded no territory to the Kingdom of Prussia after the Austrian defeat in the Austro-Prussian War, the Peace of Prague (23 August 1866) settled the German Question in favour of Prussia, which prevented the unification of Germany from occurring under the House of Habsburg. Franz Joseph was troubled by nationalism throughout his reign. He concluded the Austro-Hungarian Compromise of 1867, which both granted greater autonomy to Hungary and created the dual monarchy of Austria-Hungary. He ruled peacefully for the next 45 years, but suffered multiple personal tragedies: the execution of his brother Emperor Maximilian I of Mexico in 1867, the death by suicide of his son Rudolf in 1889, and the assassinations of first his wife Elisabeth in 1898 and then his nephew and heir presumptive, Archduke Franz Ferdinand, in 1914. After the Austro-Prussian War, Austria-Hungary turned its attention to the Balkans, then a hotspot of international tension due to Austria's interests conflicting with both the Ottoman and Russian Empires. The Bosnian Crisis resulted from Franz Joseph's 1908 annexation of Bosnia and Herzegovina, already occupied by his troops since the Congress of Berlin (1878). On 28 June 1914, the assassination of Archduke Franz Ferdinand in Sarajevo resulted in Austria-Hungary's declaration of war against the Kingdom of Serbia, an ally of the Russian Empire. This activated a system of alliances declaring war on each other, resulting in World War I. After ruling his domains for almost 68 years, Franz Joseph died in 1916.
==== MeSH D12.776.602.500.500 – oncogene proteins, fusion ==== MeSH D12.776.602.500.500.100 – fusion proteins, bcr-abl MeSH D12.776.602.500.500.320 – fusion proteins, gag-onc MeSH D12.776.602.500.500.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.602.500.500.660 – oncogene protein tpr-met
=== Emotional changes === A 2017 population-based, matched-cohort study of 93,197 men aged 66 years and older with BPH found that finasteride and dutasteride were associated with a significantly increased risk of depression (HRTooltip Hazard ratio, 1.94; 95% CITooltip Confidence interval, 1.73–2.16) and self-harm (HR, 1.88; 95% CI, 1.34–2.64) during the first 18 months of treatment, but were not associated with an increased risk of suicide (HR, 0.88; 95% CI, 0.53–1.45). After the initial 18 months of therapy, the risk of self-harm was no longer heightened, whereas the elevation in risk of depression lessened but remained marginally increased (HR, 1.22; 95% CI, 1.08–1.37). The absolute increase in the rate of depression was 247 per 100,000 patient-years and of self-harm was 17 per 100,000 patient-years. As such, on the basis of these findings, it has been stated that cases of depression in patients that are attributable to 5-ARIs will be encountered on occasion, while cases of self-harm attributable to 5-ARIs will be encountered very rarely. There were no differences in the rates of depression, self-harm, and suicide between finasteride and dutasteride, suggesting that the specific 5-ARI used does not influence the risks. The absolute risks of self-harm and depression with 5-ARIs remain low (0.14% and 2.0%, respectively).
Sources: en.wikipedia.org
== Preparation == Ethane-1,2-dithiol is made commercially by the reaction of 1,2-dichloroethane with aqueous sodium bisulfide. In the laboratory, it can also be prepared by the action of 1,2-dibromoethane on thiourea followed by hydrolysis.
=== Diana Ramdani === Diana Ramdani, née Smith (Brittany Ashworth, series 2; Emily Barber, series 3) is Rishi's fiancée and later wife. Though she and Rishi have similar personalities, Rishi struggles to get along with Diana's wealthy white family due to racial and class disparities. In series 3, Diana is a housewife raising she and Rishi's newborn on a country estate the two purchased; their marriage is strained due to mutual infidelity and Rishi's gambling addiction, which has put him in severe financial debt. The two are separated by the end of series 3, with Diana living in an apartment in the city; Rishi comes to visit her for his birthday, but his loan shark Vinay is waiting for him, revealing to Diana that Rishi owes him over half a million pounds. When Diana begins to berate Vinay for his predatory behavior, Vinay shoots her dead and escapes.
=== Medicinal === In traditional Chinese medicine, the entirety of S. affinis is used as an agent to treat colds and pneumonia. In addition, root extract of S. affinis has shown antimicrobial activity. Furthermore, Baek et al. observed antioxidant activity in 2004. Also in 2004 inhibitory effects on acetylcholine esterase, monoamine oxidase and xanthine oxidase activities were observed in rat brains after 20 days of feeding with methanolic extracts of S. affinis. Ethanol extract from this plant also seems to have antitumour activity.
In the late 1990s, Smith's group was also extensively involved in the development and application of Fourier transform ion cyclotron resonance (FTICR) mass spectrometry, which provided the basis for much greater MS resolution and mass measurement accuracy, and particularly in the development of these technologies for applications in proteomics. More recent work has centered on extending application of these proteomics technologies to mammalian systems, which pose additional challenges due to their much greater complexity. One early focus has been the human blood plasma proteome due to its broad biomedical applications. Plasma proteome measurements potentially can provide the basis for discovery of protein biomarkers or signatures for virtually every disease state. In September 1999, R&D Magazine picked the top 40 technologies of all time based on their impact on society, industry and commercial applications. The Top 40 were selected from a list of 3,600 past R&D 100 Awards. Smith was the recipient of one of these awards, for the development of capillary electrophoresis-mass spectrometry.
Sources: en.wikipedia.org
==== Renovation ==== In 1983, in an attempt to draw crowds to the park and raise money for continued maintenance, the BPRC proposed leasing Bryant Park from the city, renovating it, and building a café in the park. The $18 million renovation was to be executed by an alliance between the BPRC, NYPL, and NYC Parks. Restaurateur Warner LeRoy was to operate the eatery, and he planned to build an 80-foot-tall (24 m), 10,500-square-foot (980 m2) glass café on the park's east side adjacent to the library. In addition, the park would include four smaller food kiosks, a reflecting pool and water fountain, and a dedicated security team.
Sickle cell disorders, which are the most prevalent form of hemoglobinopathy. Sickle hemoglobin (HbS) is prone to polymerize when deoxygenated, precipitating within the red blood cell. This damages the RBC membrane resulting in its premature destruction and consequent anemia. Unstable hemoglobin variants are mutations that cause the hemoglobin molecule to precipitate, spontaneously or upon oxidative stress, resulting in hemolytic anemia. Precipitated, denatured hemoglobin can attach to the inner layer of the plasma membrane of the red blood cell (RBC) forming Heinz bodies, leading to premature destruction of the RBC and anemia. Change in oxygen affinity. High or low oxygen affinity hemoglobin molecules are more likely than normal to adopt the relaxed (R, oxy) state or the tense (T, deoxy) state, respectively. High oxygen affinity variants (R state) cause polycythemia (e.g., Hb Chesapeake, Hb Montefiore). Low oxygen affinity variants can cause cyanosis (e.g., Hb Kansas, Hb Beth Israel).
Numerous analogues and derivatives of DMT are known. Some examples include tryptamine (T), N-methyltryptamine (NMT), serotonin (5-hydroxytryptamine; 5-HT), psilocin (4-HO-DMT), psilocybin (4-PO-DMT), 4-AcO-DMT (psilacetin), 4-PrO-DMT, bufotenin (5-HO-DMT or N,N-dimethylserotonin), and 5-MeO-DMT (mebufotenin; N,N,O-trimethylserotonin). Some further examples include methylethyltryptamine (MET), diethyltryptamine (DET), methylpropyltryptamine (MPT), dipropyltryptamine (DPT), methylisopropyltryptamine (MiPT), diisopropyltryptamine (DiPT), methylallyltryptamine (MALT), diallyltryptamine (DALT), and pyr-T (N,N-tetramethylenetryptamine) and their derivatives. Some lesser-known DMT derivatives include 1-methyl-DMT, lespedamine (1-MeO-DMT), 2-methyl-DMT, 4-methyl-DMT, 4-MeO-DMT, 4-fluoro-DMT, 5-methyl-DMT, 5-ethyl-DMT, 5-TFM-DMT, 5-EtO-DMT, 5-TFMO-DMT, 5-fluoro-DMT, 5-chloro-DMT, 5-bromo-DMT, 6-fluoro-DMT, 5,6-dibromo-DMT, 4,5-MDO-DMT, 4,5-DHP-DMT, 5,6-MDO-DMT, 5-MeS-DMT, 6-methyl-DMT, 6-HO-DMT, 6-MeO-DMT, 7-methyl-DMT, 7-MeO-DMT, NBoc-DMT (NB-DMT), α,N,N-TMT (α-Me-DMT), and α,N,N,O-TeMS (5-MeO-α-Me-DMT). Cyclized tryptamines containing DMT in their chemical structures include ibogalogs like ibogainalog and tabernanthalog; iboga alkaloids like ibogaine and noribogaine; lysergamides like ergine (LSA) and lysergic acid diethylamide (LSD); and partial ergolines and lysergamides like N-DEAOP-NMT, 10,11-seco-LSD, RU-28306 (4,α-methylene-DMT), RU-28251 (4,α-methylene-DPT), Bay R 1531 (LY-197206; 4,α-methylene-5-MeO-DPT), and NDTDI (8,10-seco-LSD), among others.
Other specific agencies working on the regulation of AI included the Food and Drug Administration, which created pathways to regulate the incorporation of AI in medical imaging. The National Science and Technology Council also published an updated National Artificial Intelligence Research and Development Strategic Plan in 2019, which received public scrutiny and recommendations to further improve it towards enabling Trustworthy AI.
== See also == Anatomical pathology – Medical specialty Blood test – Laboratory analysis performed on a blood sample Clinical Laboratory Improvement Amendments – United States federal regulatory standards Diagnostics – Identification of the nature and cause of a certain phenomenonPages displaying short descriptions of redirect targets Healthcare – Prevention of disease and promotion of well-beingPages displaying short descriptions of redirect targets Histology – Study of the microscopic anatomy of cells and tissues of plants and animals Laboratory stewardship – Optimizing use of laboratory tests Pathology – Study of disease Point-of-care testing – Diagnostic testing performed at or near the point of care Associations American Society for Clinical Pathology – Medical association Association for Diagnostics & Laboratory Medicine – Global scientific society Journals Laboratory medicine journals
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.